Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-05

Study Completion Date

2019-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Based on the fact that the fundamental pathogenic mechanism of the Multiple Sclerosis (MS) disease is neuroinflammation, related in turn to cellular oxidation and mitochondrial alterations, this project aims to assess the impact of a nutritional intervention on the evolution of MS patients in their different slopes. To this end, the administration of medium-chain triglycerides, whose metabolism produces the increase of ketone bodies in the blood, will be carried out; and another of the antioxidant polyphenol epigallocatechin gallate. This procedure will be applied over 6 months, based on a isocaloric Mediterranean diet, with a population for the study of 80 patients with different variants of the disease. The assessment of the intervention will be carried out every two months, at motor-functional, anthropometric, cognitive and emotional, inflammatory, and oxidation levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Diet on Quality of Life in Multiple Sclerosis

NCT05007483

Multiple Sclerosis, Relapsing-Remitting

ACTIVE_NOT_RECRUITING NA

Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis

NCT01149525

Multiple Sclerosis

COMPLETED PHASE3

Natural Antioxidants in the Treatment of Multiple Sclerosis

NCT00010842

Multiple Sclerosis

COMPLETED PHASE1/PHASE2

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

NCT01848327

Relapsing Remitting MS Secondary Progressive MS Primary Progressive MS

COMPLETED NA

Nutritional Approaches in Multiple Sclerosis

NCT03508414

Multiple Sclerosis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Multiple Sclerosis

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Lactose

Intervention Multiple Sclerosis

Group Type EXPERIMENTAL

Coconut oil and epigallocatechin gallate

Intervention Type DIETARY_SUPPLEMENT

600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coconut oil and epigallocatechin gallate

600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)

Intervention Type DIETARY_SUPPLEMENT